Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 8/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10154969 | 0.94 | KCNH2 (0.50) | KCNH2NR1I2CYP3A4SCN5ASCN9A | |
| SCHEMBL10155283 | 0.94 | KCNH2 (0.50) | KCNH2NR1I2CYP3A4SCN5ASCN9A | |
| SCHEMBL10155332 | 0.93 | KCNH2 (0.49) | KCNH2NR1I2CYP3A4SCN5ASCN9A | |
| SCHEMBL10155803 | 0.92 | KCNH2 (0.49) | KCNH2NR1I2CYP3A4SCN5ASCN9A | |
| SCHEMBL852759 | 0.92 | KCNH2 (0.49) | KCNH2NR1I2CYP3A4SCN5ASCN9A | |
| SCHEMBL848528 | 0.92 | KCNH2 (0.49) | KCNH2NR1I2CYP3A4SCN5ASCN9A | |
| SCHEMBL850768 | 0.92 | KCNH2 (0.52) | KCNH2NR1I2CYP3A4SCN5ASCN9A | |
| SCHEMBL10155831 | 0.91 | NR1I2 (0.53) | KCNH2NR1I2CYP3A4SCN5ASCN9A | |
| SCHEMBL851576 | 0.91 | KCNH2 (0.48) | KCNH2NR1I2CYP3A4SCN5ASCN9A | |
| SCHEMBL13188157 | 0.89 | KCNH2 (0.47) | KCNH2NR1I2CYP3A4SCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2401280-B1 | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-05-01 | — | — | EP | disclosed |
| US-8143244-B2 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100216774-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216774-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | HAVCR2, EIF2AK2, HCCS | KCNH2 2055/4885NR1I2 282/4885CYP3A4 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.